TACE + immunotherapy/anti-VEGF
Adding drugs to the catheter procedure keeps intermediate-stage liver cancer under control for longer, though a survival gain is still unproven.
EMERALD-1, LEAP-012 and EMERALD-3 all improved PFS by roughly 30%; LEAP-012's final OS HR of 0.98 and EMERALD-1's non-significant OS trend leave the survival question open. Toxicity roughly doubles.
Pages like this
not linked directly; found by shared links- CompanyBoston Scientific
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- ProductTremelimumab
Shares EMERALD-3, Hepatocellular carcinoma, Immune checkpoint inhibitors.
- TermTACE (transarterial chemoembolisation)
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermPortal vein tumour thrombus (macrovascular invasion)
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- ProductCamrelizumab + rivoceranib
Shares Anti-angiogenic therapy, Hepatocellular carcinoma, Immune checkpoint inhibitors.
- TermDownstaging and conversion therapy
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- ProductLenvatinib
Shares LEAP-012, EMERALD-3, Anti-angiogenic therapy, Hepatocellular carcinoma.